Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment (scientific article published on 03 May 2012)

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Q29614889

Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.

Q30368720

Aldosterone in salt-sensitive hypertension and metabolic syndrome.

Q30369059

Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy

Q33742195

The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients

Q33815592

Physiology and pathophysiology of the adipose tissue renin-angiotensin system

Q33944511

The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension

Q34235147

Body mass index predicts aldosterone production in normotensive adults on a high-salt diet

Q35597066

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions

Q36314468

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Ph

Q36354637

The incidence and implications of aldosterone breakthrough

Q36918649

Predictive validity of a medication adherence measure in an outpatient setting

Q36925564

Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates

Q37127225

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline

Q37190775

Spironolactone Management of Resistant Hypertension

Q37803301

Obesity-related hypertension: epidemiology, pathophysiology, and clinical management

Q39848035

Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions

Q40007742

Mechanisms of angiotensin II formation in humans

Q41016873

Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range

Q43071748

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy

Q43558447

Does aldosterone modulate central control of blood pressure?

Q44002442

Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients

Q44415971

Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion

Q44725156

Serum aldosterone and the incidence of hypertension in nonhypertensive persons

Q44960387

A not-so-modest proposal that a "modest" increase in aldosterone causes hypertension and more

Q46881172

The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients

Q47282959

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Q53907739

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

Q57086150

Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients

Q57702000

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

Q63694274

Additive effects of losartan and enalapril on blood pressure and plasma active renin

Q73089154

P433

issue

P304

page(s)

818-826

P577

publication date

2012-05-03

P1433

published in

Journal of Clinical Hypertension

Q15762840

P1476

title

Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment

P478

volume

Reverse relations

cites work (P2860)

Q38108677	A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.
Q38720544	Aldosterone Production and Signaling Dysregulation in Obesity.
Q42371966	Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy
Q33715302	Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk
Q34714245	Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease
Q38211377	Hypertensive heart disease and obesity: a complex interaction between hemodynamic and not hemodynamic factors.
Q30301249	Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: a meta-analysis
Q58760700	Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury
Q48280926	Obesity and the diagnostic accuracy for primary aldosteronism.
Q35024828	Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison
Q36336748	Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists
Q89996425	Tachycardiomyopathy in Patients without Underlying Structural Heart Disease
Q92550084	The place of ARBs in heart failure therapy: is aldosterone suppression the key?

P356	DOI	10.1038/AJH.2012.47
P698	PubMed publication ID	22552267